Cefotaxime treatment for women with community-acquired pelvic abscesses.
Forty-one women with pelvic abscesses complicating salpingitis were treated with parenteral cefotaxime, a newer cephalosporin. Abscesses ranged in size from 4 by 4 to 13 by 15 cm, and in 10 women (24%) they were greater than or equal to 10 cm. Neisseria gonorrhoeae was recovered from the endocervix in 17 women (41%). A mean of 26.7 gm of cefotaxime was given over a mean of 6.5 days, and operation was not required during initial therapy. Only two women (5%) required the addition of another antimicrobial. Chronic pelvic pain and recurrent infection were infrequent during the 31- to 43-month follow-up period. Five women (12%) were readmitted for elective surgical therapy because of persistent or recurrent adnexal mass 1 to 33 months following study entry. Six (15%) women became pregnant and were delivered of their infants a mean of 25 months following cefotaxime therapy.
D000038:Abscess / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D002439:Cefotaxime / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007044:Hysterectomy; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy; D011247:Pregnancy; D011446:Prospective Studies; D012008:Recurrence; D012488:Salpingitis / Q000150:complications / Q000188:drug therapy*; D014463:Ultrasonography
D002439:Cefotaxime